Perhaps sensing the pharmaceutical industry’s growing irritation with the US Food and Drug Administration’s inability to perform timely onsite inspections and complaints about its use of remote assessments, FDA Commissioner Stephen Hahn has reiterated that the agency has resumed performing domestic inspections.
Hahn announced in a 23 November tweet that “we have resumed prioritized domestic surveillance inspections and are using all available...





